利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.057 秒)

    Phosphorus-containing thyromimetics
    3.
    发明授权
    Phosphorus-containing thyromimetics 失效
    含磷的甲状腺素

    公开(公告)号：US07829552B2

    公开(公告)日：2010-11-09

    申请号：US10580134

    申请日：2004-11-19

    申请人： Mark D. Erion ,  Hongjian Jiang ,  Serge H. Boyer

    发明人： Mark D. Erion ,  Hongjian Jiang ,  Serge H. Boyer

    IPC分类号： A61K31/66 ,  C07F9/02

    CPC分类号： C07F9/4056 ,  C07F9/301 ,  C07F9/306 ,  C07F9/3808 ,  C07F9/3882 ,  C07F9/4006 ,  C07F9/4075 ,  C07F9/4407 ,  C07F9/4465 ,  C07F9/5728 ,  C07F9/58 ,  C07F9/65517 ,  C07F9/657181

    摘要： The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.

    摘要翻译： 本发明涉及含有T3模拟物的膦酸化合物，其立体异构体，药学上可接受的盐，共晶体和前体药物以及前体药学上可接受的盐和共晶体，以及它们的制备和用途，用于预防和/或 治疗代谢疾病如肥胖，NASH，高胆固醇血症和高脂血症，以及相关病症如动脉粥样硬化，冠心病，糖耐量异常，代谢综合征和糖尿病。

    Phosphorus-containing thyromimetics
    4.
    发明授权
    Phosphorus-containing thyromimetics 失效
    含磷的甲状腺素

    公开(公告)号：US07514419B2

    公开(公告)日：2009-04-07

    申请号：US11137773

    申请日：2005-05-26

    申请人： Mark D. Erion ,  Hongjian Jiang ,  Serge H. Boyer

    发明人： Mark D. Erion ,  Hongjian Jiang ,  Serge H. Boyer

    IPC分类号： A61K31/66 ,  C07F9/02

    CPC分类号： C07F9/4056 ,  C07F9/301 ,  C07F9/306 ,  C07F9/3808 ,  C07F9/3882 ,  C07F9/4006 ,  C07F9/4075 ,  C07F9/4407 ,  C07F9/4465 ,  C07F9/5728 ,  C07F9/58 ,  C07F9/65517 ,  C07F9/657181

    摘要： The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

    摘要翻译： 本发明涉及含膦酸的T3模拟物及其单酯的化合物，其立体异构体，药学上可接受的盐，共晶体和前药以及其药学上可接受的盐和共结晶，以及它们的制备和用途 预防和/或治疗诸如肥胖，NASH，高胆固醇血症和高脂血症的代谢疾病，以及相关病症如动脉粥样硬化，冠心病，葡萄糖耐量降低，代谢综合症x和糖尿病。

    C-4' modified adenosine kinase inhibitors
    9.
    发明授权
    C-4' modified adenosine kinase inhibitors 失效
    C-4'修饰的腺苷激酶抑制剂

    公开(公告)号：US5763596A

    公开(公告)日：1998-06-09

    申请号：US660505

    申请日：1996-06-07

    申请人： Serge H. Boyer ,  Bheemarao G. Ugarkar ,  Mark D. Erion

    发明人： Serge H. Boyer ,  Bheemarao G. Ugarkar ,  Mark D. Erion

    IPC分类号： C07H19/044

    CPC分类号： C07H19/044

    摘要： This invention relates to adenosine kinase inhibitors and to nucleoside analogs, C-4' modified pyrrolo�2,3-d!pyrimidine and pyrazolo�3,4-d!pyrimidine nucleoside analogs having activity as adenosine kinase inhibitors. The invention relates to nucleoside analogs of this kind, having zero substitutions or two substitutions at the C-4' position of the furanose (sugar) moiety. The invention also relates to the preparation and use of these adenosine kinase inhibitors in the treatment of cardiovascular, and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.

    摘要翻译： 本发明涉及具有作为腺苷激酶抑制剂活性的腺苷激酶抑制剂和核苷类似物C-4'修饰的吡咯并[2,3-d]嘧啶和吡唑并[3,4-d]嘧啶核苷类似物。 本发明涉及这样的核苷类似物，其在呋喃糖（糖）部分的C-4'位置具有零取代或两个取代。 本发明还涉及这些腺苷激酶抑制剂在治疗心血管和脑血管疾病，炎症等疾病中的制备和应用，可以通过增加腺苷的局部浓度来调节。